| Name | Title | Contact Details |
|---|
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company`s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health`s wearable therapy is essential tremor, a disease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
BioCentury Publications, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. BioCentury Publications, Inc. is based in Redwood City, CA. You can find more information on BioCentury Publications, Inc. at www.biocentury.com
Since 1983, Schulman has provided the research community with IRB review services of the highest quality. In establishing the IRB, our founders sought to promote clinical research by helping to safeguard the rights and welfare of clinical research subjects. Schulman’s team of dedicated professionals seeks to provide timely, quality services based on the foundation of respect for persons, beneficence and justice. Through continuous quality improvement and rigorous training on human subject protection, Schulman provides thorough, ethical, responsive and thoughtful review of research studies. By combining impeccable review standards, savvy industry insight, responsive customer service and innovative technological solutions, Schulman creates a review experience that goes beyond the expected. We look forward to continued collaboration with our colleagues in North America and around the world as we uphold our mission to protect the rights and welfare of clinical research subjects.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.
AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. Led by an experienced surgeon team and utilizing patented viscoelastic polymer technology, AxioMed has developed the next generation of artificial discs.